Moja P, Tranchat C, Tchou I, Pozzetto B, Lucht F, Desgranges C, Genin C
Groupe Immunit¿e des Muqueuses et Agents Pathog¿enes, University of Saint Etienne, Saint Etienne, France.
J Infect Dis. 2000 May;181(5):1607-13. doi: 10.1086/315420. Epub 2000 May 8.
Infection with human immunodeficiency virus type 1 (HIV-1) has been shown to elicit a serum antibody response with neutralizing activity against T cell line-adapted HIV strains and primary HIV-1 isolates. Mucosal surfaces are the primary route of HIV-1 infection. Evidence is presented here for the presence of HIV-neutralizing antibodies in secretions. Infection of mucosal cells with HIV stimulates systemic and mucosal immune responses and results in the generation of neutralizing antibodies. Serum IgG and IgA neutralize HIV-1MN infection of susceptible T cell lines; serum IgG inhibits more effectively. Mucosal IgA purified from parotid saliva of HIV-1-seropositive individuals could neutralize both a T cell line-adapted strain and a primary isolate. The neutralizing activity of IgA was not directed against the anti-third-variable-loop or the anti-ELDKWA epitope. Thus, the specificity of mucosal IgA for HIV-1 neutralization epitopes remains to be determined and may provide insight into development of a mucosal vaccine.
已证明感染1型人类免疫缺陷病毒（HIV-1）会引发血清抗体反应，产生针对T细胞系适应型HIV毒株和原发性HIV-1分离株的中和活性。黏膜表面是HIV-1感染的主要途径。本文提供了分泌物中存在HIV中和抗体的证据。HIV感染黏膜细胞会刺激全身和黏膜免疫反应，并导致产生中和抗体。血清IgG和IgA可中和HIV-1MN对易感T细胞系的感染；血清IgG的抑制作用更有效。从HIV-1血清阳性个体的腮腺唾液中纯化的黏膜IgA可中和T细胞系适应型毒株和原发性分离株。IgA的中和活性并非针对抗第三可变环或抗ELDKWA表位。因此，黏膜IgA对HIV-1中和表位的特异性仍有待确定，这可能有助于深入了解黏膜疫苗的研发。
